Share This Author
Intracellular cysteine delivery system that protects against toxicity by promoting glutathione synthesis.
- J. Williamson, B. Boettcher, A. Meister
- Biology, ChemistryProceedings of the National Academy of Sciences…
- 1 October 1982
An intracellular cysteine delivery system was used to promote glutathione synthesis, and this was found to protect against toxicity, and the thiazolidine, which is converted to L-cysteine by the enzyme 5-oxo-L-prolinase, is the actual protectant.
Solubilization, purification, and characterization of a truncated form of rat hepatic squalene synthetase.
Overexpression, purification, and kinetic characterization of a carboxyl-terminal-truncated yeast squalene synthetase.
- P. Lograsso, D. Soltis, B. Boettcher
- Biology, ChemistryArchives of biochemistry and biophysics
- 1 November 1993
Yeast squalene synthetase which has been overexpressed in Escherichia coli and constitutes approximately 20% of the total soluble cell protein shows a preference for NAD PH over NADH as reflected in the sevenfold higher kcat/Km value for NADPH similar to that for the native enzyme.
Treatment of type 2 diabetes by adenoviral-mediated overexpression of the glucokinase regulatory protein.
In vitro experiments indicated that GK RP was able to increase both GK protein and enzymatic activity levels, suggesting that another role for GKRP is to stabilize and/or protect GK.
Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide.
- S. Hu, S. Wang, B. Boettcher
- Biology, ChemistryThe Journal of pharmacology and experimental…
- 1 May 2000
Kinetics of the inhibitory effect on K(ATP) current showed that the onset of inhibition by nateglinide was comparable to glibenclamide but more rapid than that of repaglinide.
Phenotypic correction of diabetic mice by adenovirus-mediated glucokinase expression.
The adenoviral vector-mediated overexpression of GK in a diet-induced murine model of type 2 diabetes as a treatment for diabetes suggests that the enzyme may have a therapeutic potential for the treatment of type 1 diabetes.
Cloning, expression, and characterization of human apolipoprotein(a) kringle IV37.
- P. Lograsso, S. Cornell-Kennon, B. Boettcher
- BiologyThe Journal of biological chemistry
- 26 August 1994
It is demonstrated that apo(a) KIV37 can be expressed at high levels, refolded properly, and used as a fully functional lysine-binding domain and provides the major interaction of Lp (a) with fibrinogen.
The mechanisms underlying the unique pharmacodynamics of nateglinide
Given that the kinetic profile of the agent is associated with selective enhancement of early-phase insulin secretion, nateglinide is expected to minimise post-meal hyperglycaemia with minimal propensity for hypoglycaemia.
Cevoglitazar, a novel peroxisome proliferator-activated receptor-alpha/gamma dual agonist, potently reduces food intake and body weight in obese mice and cynomolgus monkeys.
It is demonstrated that cevoglitazar holds promise for the treatment of diabetes and obesity-related disorders because of its unique beneficial effect on energy balance in addition to improving glycemic and metabolic control.
Effects of cevoglitazar, a dual PPARα/γ agonist, on ectopic fat deposition in fatty Zucker rats
- D. Laurent, J. Gounarides, J. Gao, B. Boettcher
- Medicine, BiologyDiabetes, obesity & metabolism
- 1 June 2009
Aim: By acting as both insulin sensitizers and lipid‐lowering agents, dual‐acting peroxisome proliferator‐activated receptors α/γ (PPARα/γ) agonists may be used to improve glucose tolerance in type…